Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Board of Directors
Past & Future Projects
Recent News
Donate
Contact Us
Sexualmed.org
Irwin Goldstein, MD
President and Director
Sue Goldstein
Clerk and Director
Gerald Birin
Director
Leonard DeRogatis, PHD
Director
Tom Faranda
Director
Pedram Salimpour, MD
Director
Kim Whittemore
Director
Irwin Goldstein, MD
President and DIrector
Dr. Irwin Goldstein has been involved with sexual dysfunction research since the late 1970’s. His interests include penile microvascular bypass surgery, surgery for dyspareunia, physiologic investigation of sexual function in men and women, and diagnosis and treatment of sexual dysfunction in men and women. He has authored more than 325 publications in the field of sexual dysfunction, with 20 consecutive years of funding by the National Institutes of Health in this area. He is Editor-in Chief of The Journal of Sexual Medicine, the official journal of the International Society for Sexual Medicine, its regional affiliate societies, and the International Society for the Study of Women’s Sexual Health. Dr. Goldstein has relocated to San Diego where he is Director of Sexual Medicine at Alvarado Hospital, Clinical Professor of Surgery at University of California at San Diego and Director of San Diego Sexual Medicine where he maintains his clinical practice.
Dr. Goldstein holds a bachelor’s degree in engineering from Brown University, with an honors thesis in biomedical engineering. In 1975, he graduated from McGill University Faculty of Medicine in his hometown of Montreal, Quebec, Canada. He was on the faculty of Boston University School of Medicine for 25 years where he was Professor of Urology and Gynecology and founding Director of the former Institute for Sexual Medicine at BUSM. Dr. Goldstein is currently President of The Institute for Sexual Medicine, Inc., a charitable corporation for education and research in the field. He is Secretary of the International Society for the Study of Women’s Sexual Health, a former President of the Sexual Medicine Society of North America, a board member of the International Society for Sexual Medicine and a member of the International Academy of Sex Research, the American Urological Association, the American Association of Sex Educators, Counselors and Therapists, and the International Society for the Study of Vulvovaginal Disease. Dr. Goldstein is a 2009 winner of the Gold Medal awarded by the World Association for Sexual Health in recognition of his lifetime contributions to the field.
I A gree LOL! = masnaghetti 1 month ago My comment meant for article writer not you.
Short sellers are NOT investors, they are simply speculators, manipulators, tape worms in the monetary system. They produce nothing but paper that essentially embezzles money from the productive into their parasitic pockets. Wallstreet scum represent some of the worst elements in society and epitomize a lot of what is wrong with America: something-for-nothing mentality.
This article laughingly attempts to put lipstick on the pig. Nice try dude, but most are not as stupid as you assume.
Little Femprox review 2012-
Topical Drug May Hit the Spot for Female Arousal
Published: May 24, 2012
By Charles Bankhead, Staff Writer, MedPage Today
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner
save|
A
A
Action Points
Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
Symptoms of female sexual arousal disorder (FSAD) improved significantly during treatment with a topical prostaglandin (alprostadil) compared with placebo.
Note that younger women (<45) treated with the highest concentration of the medication had the greatest improvement compared with the placebo group.
ATLANTA -- Symptoms of female sexual arousal disorder (FSAD) improved significantly during treatment with a topical prostaglandin compared with placebo, results of a randomized clinical trial showed.
Women who used alprostadil (Femprox) cream had as much as 63% improvement in the primary outcome of satisfactory sexual encounters, as defined by responses to a validated sexuality questionnaire.
Younger women (<45) treated with the highest concentration of the medication had the greatest improvement compared with the placebo group.
Women who used the highest concentration of alprostadil cream had significant improvement in all primary and secondary endpoints compared with placebo, as reported here at the American Urological Association meeting.
"I think these results are exciting," Irwin Goldstein, MD, of San Diego Sexual Medicine in California, told MedPage Today. "Women have sexual problems, and we really haven't been addressing them. We haven't been giving them choices, like men have choices, and women need choices just like men do."
Topical alprostadil was generally well tolerated, and adverse events were consistent with drug's known effects, he added.
Some women may find certain nonprescription products helpful with minor problems related to sexual arousal. However, more severe forms of FSAD have proven unresponsive to multiple therapies, including phosphodiesterase type 5 inhibitors and, most recently, topical testosterone preparations.
Alprostadil (Muse) has demonstrated efficacy in the treatment of erectile dysfunction in men. An injectable formulation is approved in the U.S. and a topical formulation has approval in Canada. The topical formulation's vehicle contains a proprietary skin-penetration enhancer that temporarily relaxes tight skin junctions to enable alprostadil delivery and penetration.
Effective tissue penetration by alprostadil results in vasodilation, smooth muscle relaxation, and increased blood flow. Men apply the cream to the head of the penis, whereas the higher dose developed for women is applied to the clitoris and distal anterior vaginal wall, considered the G spot.
"Everyone understands that when you have desire it leads to sexual activity, which is followed by blood flow to the genital tissue, causing an arousal and engorgement response," Goldstein said. "If a woman has issues with arousal, it's problematic. We understand that. That's what erectile dysfunction is in men. There's absolutely no reason not to think that there is a subgroup of women who are unhappy with their sex lives and who could improve their sex lives if they had an appropriate topical agent that's a little stronger than what is currently available."
Goldstein reported updated findings from a phase III, randomized, placebo-controlled clinical trial involving 387 Chinese women with FSAD (J Sex Med 2008; 5: 1923-1931). The study population included pre- and postmenopausal women with a mean age of 45.
The patients were randomized to placebo or one of three concentrations of alprostadil cream: 500, 700, or 900 µg. Each patient received 10 doses of randomized therapy, which was applied prior to sexual intercourse. Follow-up assessments occurred after three to five doses of therapy had been used.
The primary endpoint was defined as the proportion of women in each treatment group who answered "Yes" to Question 3 of the Female Sexual Encounter Profile: "Were you satisfied with your sexual arousal (excitement) during this sexual encounter?"
Secondary endpoints included scores on the Female Sexual Function Index (FSFI), Global Assessment Questionnaire, and the Female Sexual Distress Scale.
Overall, 33% of women allocated to placebo had improvement in satisfactory sexual encounters, compared with 46.3%, 43.5%, and 53.9% of women in the alprostadil groups (P=0.0400 to P=0.0002).
The study population consisted of 168 women ages 21 to 45 and 206 women ages 46 to 65, for a total of 374 in an intent-to-treat analysis. Evaluation of the primary endpoint by age group showed that 33% of placebo-treated patients had improvement regardless of age.
Age-stratified response rates differed across the alprostadil dose groups, but a higher proportion of women in each group had improvement compared with placebo. In the 500-µg arm, 49% of older women and 42% of younger women improved. In the 700-µg arm, 46% of younger women and 41% of older women improved.
The highest response rate occurred among younger women randomized to 900 µg of alprostadil, as they reported that 61% of sexual encounters were satisfactory (P<0.005 versus placebo). Older women had a 47% response rate.
With respect to secondary endpoints, younger women randomized to the highest concentration of topical alprostadil derived the greatest benefit versus placebo.
Moreover, only the 900 µg-arm had statistically significant improvement versus placebo for all six domains of the FSFI, regardless of patient age.
Warner Chilcott renewal deadline?http://www.trademarkia.com/vitaros-76666974.html
Good read VALUE. I never saw this before.
AUG 6TH TO BE EXACT .I also posted the facebook page .COURTFOOL IS THAT YOU = WILDBULL LOL?
I POSTED IT BEFORE WILDBULLIS THERE IS ALSO A FACEBOOK PAGE.
hentied I have no worries.Good time to have added imo.Just a matter of time and patience.
Refresher -robert.misovic robert.misovic • Jun 20, 2013 10:36 AM Flag7 users liked this posts users disliked this posts 3 Reply Big investors/Hedge funds/Tutes Sell into Rising prices..
That's almost always true. They create buzz, or use buzz, and let the price run up.. (when they want to sell).. and when they want to buy, they run the price down. Now, this stock is odd.. because what you have is something like the following breakdown. You have 3 types of investors
1. Ones who plan to hold many shares until the big pay day (long term investors)
2. Ones who buy and sell each day, short and cover every week based on trend (swing traders)
3. The one is holding for a move up, but has a set limit on a stop loss and won't stay in beyond that limit. (short term investors)
Then you have the manipulation. The goal is obviously to create volume at a very low price to allow for accumulation. How do you do that? Well.. you could short the stock in a calculated manner.. for instance, allow for super high volume on up-swing or news.. (EU/FINANCING) and accumulate a ton of shares- know that others did the same, and then, you calculated price at volume. If 500,000 shares went long at 2.88.. its safe to say at least some percentage of those shares.. perhaps 40% can be had by dragging the price to 2.40.. because thats a huge loss. Who would hold it?
Now, some people bought MORE shares expecting the price to pop at EU news. It didn't. But it should have. The Canadian approval had this stock jump.. well, news flash.. 10 EU countries have more than 10x the population of Canada. The market is enormous. But it doesn't make sense. And when it doesn't make sense, thats a good time to NOT panic, and if you can.. be #1 or #2.. proactive. Don't be #3.. a reactive sucker. Because they know all the tricks.. they know your psyche.. they know how to get you to shed shares to generate the volume.
Low volume.. what do they do?
They have Mr. X on ASK
Mr. Y on Bid
Between them they either shed a large number of shares while completely pulling any buy side orders- and then buy their own shares- as YOU see the price drop, you panic, you sell, they buy. Mission accomplished. Less
Sentiment: Buy
Dude do some research its all out.You are asking out of date questions that answers are easily found.You seem to be searching for negative where none is to be found.
Wait till market opening.Then you will imo. People want to listen before they buy.I would.
LOL! Thanks I think.
Moderator please dispose of my incorrect posts please. I will slow down in the future.
No I am not.Sorry again the page opens on IBM first.My bad.May I stay sir? :)
Very sorry! I need to slow down always looking for news.
OOPS SORRY GUYS FORGOT TO CHANGE THE SYMBOL .EMARESSING PLEASE TAKE POSTS OF THE BOARD.
Mr D. Look at this far right says 2 institutional buys on 08/01/2013 and other info below it.I am digging.https://research.tradeking.com/research/quotes/stock-financials.asp?mcsymbol=IBM&usres=yes
This is why Viaros will be huge.Look at the side effects of V and C. Viagra, Levitra and Cialis — How they're different
Although they work in similar ways, each of these medications has a slightly different chemical makeup. These minor differences affect the way each medication works, such as how quickly it takes effect and wears off, and the potential side effects. Your doctor will consider these factors when deciding if one of these medications is a good choice for you. Your doctor will also consider any health problems you have and possible interactions with other medications you take.
Viagra, Levitra
Cialis (small dose daily)
Cialis (36-hour)
How to take it Without food, no more than once a day With or without food, once a day With or without food, no more than once a day
When to take it About 30-60 minutes before sex Anytime About 30 minutes before sex
How long it's effective Up to 5 hours Anytime between doses Up to 36 hours
Vardenafil (Levitra) can also be prescribed in a tablet that dissolves on the tongue (Staxyn).
A new medication, avanafil (Stendra), was approved in April 2012 by the Food and Drug Administration for treating erectile dysfunction. Stendra works similarly to Viagra, Levitra and Cialis.
When these medications may not be safe
Not all men can safely take erectile dysfunction medications. They can be dangerous if you have certain health problems or you're taking particular medications. Erectile dysfunction medications may not be safe if you have:
•Heart problems, including reduced blood flow (aortic stenosis or left ventricular outflow obstruction), heart pain (angina), abnormal heart rhythms (arrhythmia) or a recent heart attack
•High or low blood pressure that isn't controlled
•A history of stroke within the last six months
•Eye problems, such as retinitis pigmentosa, or if you have a family history of certain eye problems
•Severe liver disease, including cirrhosis
•Kidney disease that requires dialysis
Never take Viagra, Levitra or Cialis if you take nitrate drugs to treat heart pain (angina). Like Viagra, Levitra and Cialis, nitrate drugs dilate blood vessels. Their combined effects can cause dangerously low blood pressure and loss of consciousness. Medications that contain nitrates include:
•Nitroglycerin (Nitro-Bid, Minitran, others)
•Isosorbide (Dilatrate-SR, Isordil, Monoket, others)
•Illegal drugs such as amyl nitrite or "poppers"
Tell your doctor about any medications you're taking. A number of other drugs can also interact with Viagra, Levitra or Cialis. They include:
•Alpha blockers
•Antibiotics
•Anti-seizure medications
•Blood thinners
•Anti-arrhythmic heart medications
Side effects
Most men who take Viagra, Levitra and Cialis aren't bothered by side effects. When side effects do occur, they can include:
•Headache
•Flushing (with Viagra and Levitra)
•Indigestion
•Stuffy or runny nose
•Back pain and muscle aches (with Cialis)
•Temporary vision changes, including "blue vision" (with Viagra and Levitra)
•Dizziness or fainting (rare)
In a small number of cases, men taking Viagra, Levitra or Cialis have reported more serious side effects:
•Hearing loss or vision loss. Some men have had sudden loss of hearing or loss of vision after taking one of these medications. However, it isn't clear whether vision or hearing loss was directly caused by taking the medication or by a pre-existing condition. If you're taking one of these medications for erectile dysfunction and have sudden loss of hearing or vision, seek medical help right away.
•An erection that doesn't go away on its own. Called priapism, this rare condition can be painful and requires medical treatment to avoid damage to your penis. If you have an erection that lasts more than four hours, seek medical attention.
Not the greatest chart reader, but looks like short % went up as well, along with the price.http://www.shortanalytics.com/getshortchart.php?tsymbol=APRI
They have to start covering sometime and it will not take that much news imo to get that started. There is no bad news coming imo only good. wE SHALL SEE.
Maybe the shorts will be worried with the Monday am c call and cover a little.Shorts should be a little stressed with this news imo.
Yesterday =
Apricus Biosciences Inc
(APRI:NASDAQ)
Follow Instrument
Event Lookup
Plan a Stop
Add Alert
? Options Available
Industry: Pharmaceuticals, Biotech and Chemicals
Competitors: none Add Competitor
Event Details for: Triple Moving Average Crossover
Rate this Event:
Tells Me: The price is generally in an established trend (bullish or bearish) for the time horizon represented by the moving average periods. Moving averages are used to smooth out the volatility or "noise" in the price series, to make it easier to discover the underlying trend. By plotting the average price over the last several bars, the line is less "jerky" than plotting the actual prices. In the triple crossover method, a bullish signal is generated when a faster moving average (4 bar) crosses above an intermediate moving average (9 bar), which in turn crosses above a slower moving average (18 bar). In this state, the price is likely in an established uptrend. The opposite is true when the 4 bar crosses below the 9 bar which in turn crosses below the 18 bar, triggering a bearish event. More...
Event Date: Aug 07, 2013
Opportunity Type: Short-Term Bullish
Close Price: $2.21
Price Period: Daily
Volume: 182,825
4-day moving average crossed above
the 9-day which subsequently crossed above the 18-day.
:) Short chart update= http://www.shortanalytics.com/getshortchart.php?tsymbol=apri
Hello and welcome to the APRI board.
This shows earnings on 08/09/2013 not the 8th now.http://www.nasdaq.com/earnings/report/apri
:) lol.
Here you go :) carlobd 1978 - http://www.pfo.org/revealed.htm :)
Try this link wildbullus = http://www.stockmarketstudy.org/wordpress/apricus-biosciences-inc-special-call/ read lower part of page.
Thanks for the help Mr. DIMITRIOS.
And as far as Abbott I DO NOT THINK ANYONE KNOWS THAT ANSWER YET. Good luck.
No has nothing to do with launch. Can someone with better writing skills answer for him.Mr. D OR Mr. Ecoman Mr. carlob Mr .value 1008.Or scan the post going back a bit all info is in the past posts that your are looking for.
People should be buying the drops on apri and market overall.I started investing because of Qe 1 year after they implemented it.I had a total of 27 stocks at one time and sold all 20 out of 19 at a profit 1 at a loss of only $80.00 still own 7 one of them being APRI.Up 11.2% for the year even with APRI down.It took patience and wish I had not sold all, but I added to my Apri shares, and Apri is and will be my Gold Mine. Our GOLD MINE.
Kinda expected it.Short attack before earnings and news.Scare the weak hands out.
This should take you to the facebook page. = https://www.facebook.com/AlprostadilCream?ref=hl